A Pill That Keeps Your Throat Awake Could Transform Sleep Apnea Treatment

The moment you fall asleep, your throat starts forgetting what it’s supposed to do. Not all at once. It’s a gradual withdrawal, a quieting of the neural signals that spend every waking hour keeping the muscles of your upper airway taut and open. In people with obstructive sleep apnea, that nightly retreat goes too far. The airway sags. It collapses. Breathing stops, the brain fires off an alarm, you half-rouse without knowing it, and then the whole cycle begins again, dozens, sometimes hundreds of times a night.

For decades, the only real answer was a machine. The continuous positive airway pressure device, or CPAP, essentially splints the airway open with a stream of pressurised air delivered through a mask strapped to the face. It works, when people use it. Many don’t. They find the mask claustrophobic, or the noise intolerable, or they simply wake one morning and decide they’ve had enough. By some estimates nearly half of patients abandon CPAP within a year. And that matters, because obstructive sleep apnea affects something like a billion people globally, raising their risk of heart disease, stroke, cognitive decline, and early death, mostly through the cumulative oxygen deprivation that comes with a night’s worth of interrupted breathing.

So the question researchers have been circling for years is a deceptively simple one: could you take a pill instead?

Targeting the Root Cause

A large phase 3 clinical trial presented this week at the American Thoracic Society’s international conference suggests, for perhaps the first time in a convincing and scalable way, that the answer might be yes. The drug is called AD109, and what makes it unusual is that it doesn’t treat the symptoms of sleep apnea so much as go after the underlying machinery of why the airway collapses in the first place.

The mechanism, worked out over decades of painstaking neuroscience in animal models, centres on a structure deep in the brainstem called the hypoglossal motor nucleus, the neural hub that controls the tongue and surrounding muscles keeping the throat open. During wakefulness, this nucleus receives a steady stream of excitatory input, particularly from the noradrenergic system. At sleep onset, that excitatory drive falls away. In REM sleep, a second inhibitory mechanism kicks in via muscarinic receptors linked to potassium channels, suppressing motor activity even further. The airway, deprived of its neural scaffolding, is left to fend for itself against gravity and anatomy.

AD109 is designed to counteract both mechanisms simultaneously. One component, atomoxetine, is a norepinephrine reuptake inhibitor (familiar from its use in ADHD) that boosts the excitatory noradrenergic drive to the motor neurons. The other, aroxybutynin, is a selective antimuscarinic that blocks the REM-related inhibitory pathway. Together, in theory, they keep the throat’s muscles somewhat more awake than the rest of you.

The SynAIRgy trial enrolled 646 adults across 69 centres in the US and Canada, all of them diagnosed with mild to severe obstructive sleep apnea and all of them either unwilling or unable to tolerate CPAP. They were randomised to AD109 or placebo for six months. The results, simultaneously published in the American Journal of Respiratory and Critical Care Medicine, showed a model-estimated 44 percent reduction in breathing interruptions per hour among those taking the drug, compared with about 18 percent in the placebo group. More than 40 percent of patients improved their disease severity category, and roughly 18 percent achieved what the trial classified as complete disease control.

Not a Cure, but Perhaps Enough

Patrick Strollo, a sleep medicine physician at the University of Pittsburgh Medical Center and the trial’s first author, framed the findings in terms of what he described as a troubling double standard in chronic disease care. “In many other chronic diseases, such as cardiovascular disease, asthma, or type 2 diabetes, it would be unthinkable for the majority of diagnosed patients to remain untreated or undertreated. Yet that remains the reality in OSA,” he said. “An oral pill that targets the underlying neuromuscular drivers of airway collapse during sleep could help address this gap and broaden the range of effective options for patients who remain untreated today.”

It’s worth dwelling on the numbers a bit before getting swept up in the optimism, though. AD109 isn’t doing what CPAP does. CPAP, when used properly, can bring breathing interruptions close to zero. The drug shifted the median patient from the moderate severity range down into mild (meaningful, perhaps, in terms of long-term cardiovascular risk, but not elimination). And about one in five patients discontinued the drug because of side effects: dry mouth, insomnia, nausea, urinary hesitation, all predictable from the pharmacology. The REM-suppressing effects of atomoxetine, in particular, raise questions about long-term sleep architecture that haven’t yet been answered. Small increases in heart rate and blood pressure were also recorded, which could matter for patients with underlying cardiac conditions.

Still, a companion mechanistic review published simultaneously in the American Journal of Respiratory Cell and Molecular Biology makes a case that the improvement in oxygen levels: specifically in what researchers call hypoxic burden, a measure of how deeply and for how long blood oxygen falls during sleep. That metric may translate into real cardiovascular protection over time. That metric has been more strongly linked to heart disease outcomes than the standard count of breathing interruptions, and AD109 reduced it by nearly 45 percent in the trial’s intent-to-treat analysis.

“These results provide encouraging evidence that targeting neuromuscular dysfunction can translate into meaningful clinical outcomes, aligning with our evolving understanding of the disease biology,” Strollo said.

A More Personalised Future

The drug’s manufacturer, Apnimed, has submitted a New Drug Application to the FDA. Under a Fast Track designation, a decision is expected by early 2027. If approved, AD109 would be only the second pharmacological therapy ever cleared specifically for obstructive sleep apnea; tirzepatide, a GLP-1 receptor agonist originally developed for diabetes, gained approval last year primarily for obese patients by reducing the weight pressing down on the airway.

AD109 works rather differently, and in a population that includes plenty of people who aren’t obese (a third of the SynAIRgy participants had a normal or overweight BMI). That’s important because OSA has long been misunderstood as primarily a disease of the overweight middle-aged man. Recent epidemiology has corrected that picture substantially: the condition is broadly distributed across sexes, body types, and ages, with the neuromuscular dysfunction at its core present to some degree in virtually all sufferers.

The researchers are already thinking about combinations. Patients with a strong anatomical component might do best pairing AD109 with a GLP-1 drug to reduce airway crowding from excess tissue. Those with ventilatory instability (where the breathing control system itself oscillates too easily) might benefit from adding sulthiame, a carbonic anhydrase inhibitor in phase 2 trials that targets that particular trait. The vision, in other words, is a field that stops giving everyone the same mask and starts asking which mechanism, or combination of mechanisms, is most to blame in each individual patient.

That’s perhaps where the real significance of this week’s results sits. Not in a single drug’s modest effect sizes, but in the confirmation that the neuromuscular machinery controlling the sleeping throat is, as one mechanistic review puts it, a tractable therapeutic target. The brain tells your throat to stay open. During sleep, it gets quieter. Now there’s evidence that pharmacology can turn the volume back up.

https://doi.org/10.1093/ajrccm/aamag215

Frequently Asked Questions

What is AD109 and how does it differ from CPAP?

AD109 is a once-nightly oral pill combining two existing compounds, atomoxetine and aroxybutynin, designed to keep the throat’s muscles more active during sleep by targeting the brain signals that normally quiet them. CPAP, by contrast, mechanically forces the airway open with pressurised air through a mask. AD109 doesn’t eliminate breathing interruptions the way CPAP can when used correctly, but it requires no equipment and could be a practical option for the large number of patients who find the mask intolerable.

Why do so many sleep apnea patients go untreated?

The dominant treatment, CPAP, has a significant adherence problem: roughly half of patients stop using it within a year, often because the mask is uncomfortable, claustrophobic, or disruptive to sleep. Other options such as oral appliances and surgical procedures work for some patients but have limited applicability. The result is that many people with a diagnosed condition linked to heart disease, stroke, and cognitive decline receive no meaningful treatment at all.

What are the main side effects of AD109?

The most common side effects in the trial were dry mouth, nausea, insomnia, and urinary hesitation, all consistent with the drug’s pharmacological actions. About one in five patients discontinued because of these effects, with most dropouts happening in the early weeks of treatment. The drug also suppresses REM sleep somewhat and causes small increases in heart rate and blood pressure, which means it may not suit patients with uncontrolled cardiac conditions.

Does AD109 work for everyone with sleep apnea?

The trial included patients across the full range of disease severity, body types, and sexes, and improvements were broadly consistent across subgroups. That said, response was variable: roughly 18 percent achieved near-complete disease control, while others saw more modest reductions. Researchers suspect that matching patients to treatments based on which physiological mechanism most drives their sleep apnea could substantially improve outcomes in future.

When might AD109 become available?

Apnimed, the company developing AD109, has submitted a New Drug Application to the US Food and Drug Administration. The FDA has given the drug Fast Track status, which accelerates review for conditions with significant unmet need. A regulatory decision is anticipated in the first quarter of 2027, though approval is not guaranteed and would initially apply to patients who cannot tolerate or have refused CPAP therapy.